Pharmacokinetics and Safety of Indinavir in Human Immunodeficiency Virus-Infected Pregnant Women-Reference-Cited by-同舟云学术

Pharmacokinetics and Safety of Indinavir in Human Immunodeficiency Virus-Infected Pregnant Women

Published:2007-02 Issue:2 Volume:51 Page:783-786
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Unadkat Jashvant D.¹,Wara Diane W.²,Hughes Michael D.³,Mathias Anita A.¹,Holland Diane T.⁴,Paul Mary E.⁵,Connor James⁴,Huang Sharon³,Nguyen Bach-Yen⁶,Watts D. Heather⁷,Mofenson Lynne M.⁷,Smith Elizabeth⁸,Deutsch Paul⁶,Kaiser Kathleen A.⁹,Tuomala Ruth E.¹⁰

Affiliation:

1. Department of Pharmaceutics, University of Washington, Seattle, Washington

2. Department of Pediatrics, University of California San Francisco, San Francisco, California

3. Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts

4. Division of Clinical Pharmacology and Developmental Therapeutics, University of California, San Diego, California

5. Baylor College of Medicine, Houston, Texas

6. Merck Research Laboratories, West Point, Pennsylvania

7. Pediatric Adolescent and Maternal AIDS Branch, National Institute of Child Health and Human Development, Bethesda, Maryland

8. Pediatric Medical Branch, Therapeutics Research Plan, Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland

9. Frontier Science and Technology Research Foundation

10. Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, Massachusetts

Abstract

ABSTRACT Human immunodeficiency virus-infected women ( n = 16) received indinavir (800 mg three times a day) plus zidovudine plus lamivudine from 14 to 28 weeks of gestation to 12 weeks postpartum. Two women and eight infants experienced grade 3 or 4 toxicities that were possibly treatment related. Indinavir area under the plasma concentration-time curve was 68% lower antepartum versus postpartum, suggesting increased intestinal and/or hepatic CYP3A activity during pregnancy.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00420-06

Reference13 articles.

1. AIDS Clinical Trials Group. 1996. Table of grading severity of adult adverse experiences. Division of AIDS National Institute of Allergy and Infectious Diseases Rockville MD.

2. Transendothelial migration of leukocytes carrying infectious HIV-1: an indicator of adverse prognosis

3. Bean, P. 2000. HIV's pharmacokinetics, pharmacodynamics, pharmacogenetics, and pharmacogenomics. Am. Clin. Lab.19:12.

4. Centers For Disease Control and Prevention. 1998. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. Morb. Mortal. Wkly. Rep.47:1-20.

5. Choo, E. F., B. Leake, C. Wandel, H. Imamura, A. J. Wood, G. R. Wilkinson, and R. B. Kim. 2000. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab. Dispos.28:655-660.

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quantification of sertraline maternal/fetal ratio and amniotic fluid concentration using a pregnancy physiologically based pharmacokinetic model;British Journal of Clinical Pharmacology;2023-07-07

2. Principles of Obstetric Pharmacology;Obstetrics and Gynecology Clinics of North America;2023-03

3. Impact of Pregnancy and Vitamin A Supplementation on CYP2D6 Activity;The Journal of Clinical Pharmacology;2022-11-15

4. Prediction of Maternal and Fetal Doravirine Exposure by Integrating Physiologically Based Pharmacokinetic Modeling and Human Placenta Perfusion Experiments;Clinical Pharmacokinetics;2022-05-17

5. Drug therapy in pregnant and nursing women;Atkinson's Principles of Clinical Pharmacology;2022